Castle Biosciences, Inc. Stock 12‑Month Price Target Raised to $43, Implies 61% Upside

Castle Biosciences, Inc. (CSTL) has seen its average 12-month price target raised from $42.78 to $43 by 9 analysts, implying a 61% potential upside based on the July 30 closing price. Forecasts for the stock range from $35 to $52 per share, and the consensus rating among all covering analysts remains a "Buy."